BRAF and ameloblastoma: We also demonstrated that knockdown of SOX2 leads to decreased viability of ameloblastoma cells, and increased expression of SOX2 was associated with resistance to anti-BRAF small molecule inhibitors, vemurafenib and dabrafenib, in ameloblastoma cells.